Literature DB >> 22492520

Relationship between angiographic vasospasm and regional hypoperfusion in aneurysmal subarachnoid hemorrhage.

Rajat Dhar1, Michael T Scalfani, Spiros Blackburn, Allyson R Zazulia, Tom Videen, Michael Diringer.   

Abstract

BACKGROUND AND
PURPOSE: Angiographic vasospasm frequently complicates subarachnoid hemorrhage and has been implicated in the development of delayed cerebral ischemia. Whether large-vessel narrowing adequately accounts for the critical reductions in regional cerebral blood flow underlying ischemia is unclear. We sought to clarify the relationship between angiographic vasospasm and regional hypoperfusion.
METHODS: Twenty-five patients with aneurysmal subarachnoid hemorrhage underwent cerebral catheter angiography and 15O-positron emission tomographic imaging within 1 day of each other (median of 7 days after subarachnoid hemorrhage). Severity of vasospasm was assessed in each intracranial artery, whereas cerebral blood flow and oxygen extraction fraction were measured in 28 brain regions distributed across these vascular territories. We analyzed the association between vasospasm and perfusion and compared frequency of hypoperfusion (cerebral blood flow<25 mL/100 g/min) and oligemia (low oxygen delivery with oxygen extraction fraction≥0.5) in territories with versus without significant vasospasm.
RESULTS: Twenty-four percent of 652 brain regions were supplied by vessels with significant vasospasm. Cerebral blood flow was lower in such regions (38.6±12 versus 48.7±16 mL/100 g/min), whereas oxygen extraction fraction was higher (0.48±0.19 versus 0.37±0.14, both P<0.001). Hypoperfusion was seen in 46 regions (7%), but 66% of these were supplied by vessels with no significant vasospasm; 24% occurred in patients without angiographic vasospasm. Similarly, oligemia occurred more frequently outside territories with vasospasm.
CONCLUSIONS: Angiographic vasospasm is associated with reductions in cerebral perfusion. However, regional hypoperfusion and oligemia frequently occurred in territories and patients without vasospasm. Other factors in addition to large-vessel narrowing must contribute to critical reductions in perfusion.

Entities:  

Mesh:

Year:  2012        PMID: 22492520      PMCID: PMC3383942          DOI: 10.1161/STROKEAHA.111.646836

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  35 in total

1.  Clazosentan, an endothelin receptor antagonist, in patients with aneurysmal subarachnoid haemorrhage undergoing surgical clipping: a randomised, double-blind, placebo-controlled phase 3 trial (CONSCIOUS-2).

Authors:  R Loch Macdonald; Randall T Higashida; Emanuela Keller; Stephan A Mayer; Andy Molyneux; Andreas Raabe; Peter Vajkoczy; Isabel Wanke; Doris Bach; Aline Frey; Angelina Marr; Sébastien Roux; Neal Kassell
Journal:  Lancet Neurol       Date:  2011-06-02       Impact factor: 44.182

2.  Brain blood flow measured with intravenous H2(15)O. II. Implementation and validation.

Authors:  M E Raichle; W R Martin; P Herscovitch; M A Mintun; J Markham
Journal:  J Nucl Med       Date:  1983-09       Impact factor: 10.057

3.  Cerebral blood flow evaluation of prolonged experimental vasospasm.

Authors:  F A Simeone; P J Trepper; D J Brown
Journal:  J Neurosurg       Date:  1972-09       Impact factor: 5.115

4.  Cerebral vasospasm after subarachnoid hemorrhage: an update.

Authors:  R C Heros; N T Zervas; V Varsos
Journal:  Ann Neurol       Date:  1983-12       Impact factor: 10.422

5.  Database of normal human cerebral blood flow, cerebral blood volume, cerebral oxygen extraction fraction and cerebral metabolic rate of oxygen measured by positron emission tomography with 15O-labelled carbon dioxide or water, carbon monoxide and oxygen: a multicentre study in Japan.

Authors:  Hiroshi Ito; Iwao Kanno; Chietsugu Kato; Toshiaki Sasaki; Kenji Ishii; Yasuomi Ouchi; Akihiko Iida; Hidehiko Okazawa; Kohei Hayashida; Naohiro Tsuyuguchi; Kazunari Ishii; Yasuo Kuwabara; Michio Senda
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-01-17       Impact factor: 9.236

6.  Relation of cerebral vasospasm to subarachnoid hemorrhage visualized by computerized tomographic scanning.

Authors:  C M Fisher; J P Kistler; J M Davis
Journal:  Neurosurgery       Date:  1980-01       Impact factor: 4.654

7.  Correlation between angiographic vasospasm, hematoma, and ischemic brain damage following SAH.

Authors:  D I Graham; P Macpherson; L H Pitts
Journal:  J Neurosurg       Date:  1983-08       Impact factor: 5.115

8.  Effects of subarachnoid hemorrhage on cerebral blood volume, blood flow, and oxygen utilization in humans.

Authors:  R L Grubb; M E Raichle; J O Eichling; M H Gado
Journal:  J Neurosurg       Date:  1977-04       Impact factor: 5.115

9.  Predictors of cerebral infarction in aneurysmal subarachnoid hemorrhage.

Authors:  Alejandro A Rabinstein; Jonathan A Friedman; Stephen D Weigand; Robyn L McClelland; Jimmy R Fulgham; Edward M Manno; John L D Atkinson; Eelco F M Wijdicks
Journal:  Stroke       Date:  2004-06-24       Impact factor: 7.914

10.  Positron emission tomographic cerebral perfusion disturbances and transcranial Doppler findings among patients with neurological deterioration after subarachnoid hemorrhage.

Authors:  Pawan S Minhas; David K Menon; Piotr Smielewski; Marek Czosnyka; Peter J Kirkpatrick; John C Clark; John D Pickard
Journal:  Neurosurgery       Date:  2003-05       Impact factor: 4.654

View more
  28 in total

1.  Effect of High-Dose Simvastatin on Cerebral Blood Flow and Static Autoregulation in Subarachnoid Hemorrhage.

Authors:  Michael N Diringer; Rajat Dhar; Michael Scalfani; Allyson R Zazulia; Michael Chicoine; William J Powers; Colin P Derdeyn
Journal:  Neurocrit Care       Date:  2016-08       Impact factor: 3.210

2.  SANGUINATE™ (PEGylated Carboxyhemoglobin Bovine) Improves Cerebral Blood Flow to Vulnerable Brain Regions at Risk of Delayed Cerebral Ischemia After Subarachnoid Hemorrhage.

Authors:  Rajat Dhar; Hemant Misra; Michael N Diringer
Journal:  Neurocrit Care       Date:  2017-12       Impact factor: 3.210

3.  Assessment of a multi-layered diffuse correlation spectroscopy method for monitoring cerebral blood flow in adults.

Authors:  Kyle Verdecchia; Mamadou Diop; Albert Lee; Laura B Morrison; Ting-Yim Lee; Keith St Lawrence
Journal:  Biomed Opt Express       Date:  2016-08-24       Impact factor: 3.732

Review 4.  What is new in neurocritical care: 2012.

Authors:  Nino Stocchetti
Journal:  Intensive Care Med       Date:  2013-03       Impact factor: 17.440

Review 5.  Cerebral artery myogenic reactivity: The next frontier in developing effective interventions for subarachnoid hemorrhage.

Authors:  Darcy Lidington; Jeffrey T Kroetsch; Steffen-Sebastian Bolz
Journal:  J Cereb Blood Flow Metab       Date:  2017-11-14       Impact factor: 6.200

6.  Haptoglobin phenotype predicts the development of focal and global cerebral vasospasm and may influence outcomes after aneurysmal subarachnoid hemorrhage.

Authors:  Jenna L Leclerc; Spiros Blackburn; Dan Neal; Nicholas V Mendez; Jeffrey A Wharton; Michael F Waters; Sylvain Doré
Journal:  Proc Natl Acad Sci U S A       Date:  2015-01-12       Impact factor: 11.205

Review 7.  Postoperative ICU management of patients after subarachnoid hemorrhage.

Authors:  Shaun E Gruenbaum; Fedrico Bilotta
Journal:  Curr Opin Anaesthesiol       Date:  2014-10       Impact factor: 2.706

8.  Reproduction of consistent pulse-waveform changes using a computational model of the cerebral circulatory system.

Authors:  Mark Connolly; Xing He; Nestor Gonzalez; Paul Vespa; Joe DiStefano; Xiao Hu
Journal:  Med Eng Phys       Date:  2014-01-03       Impact factor: 2.242

Review 9.  Clinical relevance of cerebral autoregulation following subarachnoid haemorrhage.

Authors:  Karol P Budohoski; Marek Czosnyka; Peter J Kirkpatrick; Peter Smielewski; Luzius A Steiner; John D Pickard
Journal:  Nat Rev Neurol       Date:  2013-02-19       Impact factor: 42.937

Review 10.  Cerebral Microdialysis in Neurocritical Care.

Authors:  Ting Zhou; Atul Kalanuria
Journal:  Curr Neurol Neurosci Rep       Date:  2018-10-23       Impact factor: 5.081

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.